New shingles vaccine shows promise in Head-to-Head trial

NCT ID NCT06581575

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Immorna Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix, and researchers will monitor side effects and immune markers over several months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER (HZ) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER (HZ) INFECTIOUS DISEASES SHINGLES

Contacts and locations

Locations

DM Clinical Research - Chicago

Chicago, Illinois, 60652, United States
DM Clinical Research - New Jersey

Jersey City, New Jersey, 07306, United States
DM Clinical Research - Sugarland

Sugar Land, Texas, 77478, United States
Delricht Research

Charleston, South Carolina, 29407, United States
Delricht Research

Prosper, Texas, 75078, United States
Long Beach Research Institute

Long Beach, California, 90805, United States
Noble Clinical Research

Tucson, Arizona, 85704, United States
Quality Clinical Research

Omaha, Nebraska, 68114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.